Nature Reviews Clinical Oncology - Table of Contents alert Volume 12 Issue 6

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
June 2015 Volume 12 Number 6
Impact Factor 15.696 *	In this issue Research Highlights News and Views Corrigendum Reviews Correspondence Also this month  Featured article: Pancreatic cancer: from state-of-the-art treatments to promising novel therapies Ignacio Garrido-Laguna & Manuel Hidalgo
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
Epigenome Roadmap Nature Publishing Group presents an online portal - the Epigenome Roadmap - which collects key research papers from The NIH Roadmap Epigenomics Program, complemented by thematical 'threads' to help the readers mine the wealth of available information. Access the Epigenome Roadmap for FREE at:  nature.com/epigenomeroadmap Produced with exclusive support from Illumina
RESEARCH HIGHLIGHTS Top Cell signalling: Cancer's vast secretes revealed—secretome changes promote resistance to therapy Published online: 21 April 2015 p309 | doi:10.1038/nrclinonc.2015.76 PDF Immunotherapy: CheckMate—has nivolumab beaten melanoma? Published online: 07 April 2015 p310 | doi:10.1038/nrclinonc.2015.67 PDF Prostate cancer: New biomarker panel prognosticates patient survival Published online: 07 April 2015 p310 | doi:10.1038/nrclinonc.2015.68 PDF Immunotherapy: Combined immunoradiotherapy reinvigorates antitumour immunity Published online: 24 March 2015 p311 | doi:10.1038/nrclinonc.2015.54 PDF Immunotherapy: Soluble ligands—a new approach to cancer therapy Published online: 24 March 2015 p311 | doi:10.1038/nrclinonc.2015.60 PDF In the news: From TAT 2015 Published online: 07 April 2015 p311 | doi:10.1038/nrclinonc.2015.64 PDF Haematological cancer: AETHERA—brentuximab wings its way as new standard of care in HL Published online: 14 April 2015 p312 | doi:10.1038/nrclinonc.2015.69 PDF IN BRIEF Targeted therapies: Alisertib tested in patients with solid tumours | Genetics: New genomic alterations detected in pancreatic cancer | Breast cancer: Meta-analysis reveals new breast cancer risk loci | Paediatric cancer: Adrenocortical cancer mutations are prognostic for survival PDF Clinical Oncology JOBS of the week Postdoctoral Fellow – Antibody engineering / Immuno-oncology (#79000) California Institute for Biomedical Research Medical Oncologist with focus on early phase clinical trials Institut Curie Postdoctoral Position In Biomolecular NMR Institute for Research in Biomedicine (IRB Barcelona) Postdoctoral Fellow Positions Openings UCLA David Geffen School of Medicine - Obstetrics and Gynecology Research Fellow University of Michigan, Department of Otolaryngology-Head and Neck Surgery More Science jobs from Clinical Oncology EVENT 3rd International Oncology Conference 10.09.15 Abu Dhabi More science events from
NEWS AND VIEWS		Top
Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials Robert S. Kerbel & Axel Grothey Published online: 12 May 2015 p313 | doi:10.1038/nrclinonc.2015.89 Investigational metronomic chemotherapy involves frequent, regularly spaced, long-term administration of a sub-maximum tolerated dose. The phase III CAIRO3 trial evaluated continuous metronomic oral capecitabine, with bevacizumab, as a maintenance treatment in patients with metastatic colorectal cancer; a benefit in progression-free survival compared with observation only was observed, highlighting that metronomic chemotherapy could be a less toxic and convenient therapy. Full Text | PDF
Gastrointestinal cancer: Effect of lymphadenectomy on survival in oesophageal cancer Bo Jan Noordman & J. Jan B. van Lanschot Published online: 12 May 2015 p315 | doi:10.1038/nrclinonc.2015.91 In patients with oesophageal cancer, the effect of lymphadenectomy on survival remains unclear. A recent retrospective cohort study suggests that extensive lymphadenectomy does not improve survival and might even hamper it in patients with early T-stage tumours. The available data show conflicting results and the introduction of neoadjuvant chemoradiotherapy might decrease any positive effect of extensive lymphadenectomy on survival. Full Text | PDF
Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? Bobby C. Liaw & William K. Oh Published online: 28 April 2015 p316 | doi:10.1038/nrclinonc.2015.79 In the recent MAINSAIL trial, addition of lenalidomide to docetaxel for metastatic castration-resistant prostate cancer (mCRPC) was associated with inferior overall survival and more toxicity; thus, lenalidomide joins a long line of agents that failed to improve the efficacy of docetaxel. The process by which new therapies are advanced to phase III studies, particularly in combination with docetaxel, should be re-examined. Full Text | PDF
CORRIGENDUM		Top
Corrigendum: Management of locally advanced breast cancer—perspectives and future directions Konstantinos Tryfonidis, Elzbieta Senkus, Maria J. Cardoso & Fatima Cardoso Published online: 14 April 2015 p312 | doi:10.1038/nrclinonc.2015.74 Full Text | PDF
REVIEWS		Top
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies Ignacio Garrido-Laguna & Manuel Hidalgo Published online: 31 March 2015 p319 | doi:10.1038/nrclinonc.2015.53 The survival rates of patients with pancreatic cancer are low and have not improved significantly over the past three or four decades. Thus, effective treatments for this disease are an urgent unmet need. Novel treatment paradigms will probably be required, and many new therapeutic approaches are being tested in this setting. This Review outlines the state-of-the-art therapies for patients with pancreatic cancer, as well as the novel treatment strategies that are the focus of drug-development efforts. Abstract | Full Text | PDF
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy Tari A. King & Monica Morrow Published online: 07 April 2015 p335 | doi:10.1038/nrclinonc.2015.63 Although neoadjuvant chemotherapy (NACT) does not prolong survival compared with adjuvant chemotherapy, this approach does not increase the risk of locoregional recurrence, and the high rates of response following NACT have had a considerable impact on locoregional treatment considerations. In particular, NACT can decrease the need for mastectomy and axillary lymph-node dissection. This Review discusses issues relating to the identification of ideal candidates for NACT, and also those surrounding surgery of the breast and axilla in women with breast cancer who receive NACT. Abstract | Full Text | PDF
Genomics in acute lymphoblastic leukaemia: insights and treatment implications Kathryn G. Roberts & Charles G. Mullighan Published online: 17 March 2015 p344 | doi:10.1038/nrclinonc.2015.38 The development and implementation of more effective genome analysis technologies has enabled substantial improvements in our understanding of the genomic changes that take place in patients with acute lymphoblastic leukaemia (ALL). This Review provides a detailed summary of advances in our understanding of the genomics of ALL, and describes how these advances might lead to improved patient outcomes. Abstract | Full Text | PDF
Patient-reported outcomes as end points and outcome indicators in solid tumours Angeles A. Secord, Robert L. Coleman, Laura J. Havrilesky, Amy P. Abernethy, Gregory P. Samsa & David Cella Published online: 10 March 2015 p358 | doi:10.1038/nrclinonc.2015.29 Patient-reported outcome (PRO) measures, such as quality of life, have been associated with relevant clinical end points and are prognostic for survival outcomes in a variety of solid cancers in adults. The authors of this Review comprehensively assess the correlation of PROs with treatment response and survival, and explore tumour-related and patient-centric composite end points in patients with cancer participating in clinical trials. Abstract | Full Text | PDF
CORRESPONDENCE		Top
The need for post-mastectomy radiotherapy in patients with IBC Gustavo Ruiz Ares, Eva Ciruelos & Luis Manso Published online: 28 April 2015 p370 | doi:10.1038/nrclinonc.2015.13-c1 Full Text | PDF
REPLY		Top
The need for post-mastectomy radiotherapy in patients with IBC Konstantinos Tryfonidis, Elzbieta Senkus, Maria J. Cardoso & Fatima Cardoso Published online: 28 April 2015 p370 | doi:10.1038/nrclinonc.2015.13-c2 Full Text | PDF
Advertisement
Nature Outlook: Colorectal Cancer Colorectal cancer is the world?s fourth most deadly cancer, killing almost 700,000 people every year. And it is expected to become more common as more people adopt Western diets and lifestyles, which are implicated as risk factors. But research into screening, prevention and treatments is helping to fight the disease.  Access the Outlook free online for six months. Produced with support from: Hoffman-La Roche Ag and Eli Lilly & Company.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2013. Nature Reviews Clinical Oncology was previously published as Nature Clinical Practice Oncology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.